Clinical trials: Ampicillin

Pneumonia, Bacterial

The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)

• Completed
• Age: 16 to 79 years
• Phase 3
• Results posted

Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet been approved in Japan.

Trial name

NCT01189487

Testing

ampicillin sodium/sulbactam sodium

Where

22 sites in Japan

Volunteers

47 people

Sponsor

Pfizer